Process for modifying drug crystal formation

Details for Australian Patent Application No. 2007202693 (hide)

Owner Novartis AG

Inventors Wieckhusen, Dierk; Pfeffer, Sabine

Agent Davies Collison Cave

Pub. Number AU-B-2007202693

Parent 2004206731

Filing date 12 June 2007

Wipo publication date 5 July 2007

Acceptance publication date 10 December 2009

International Classifications

A61K 9/14 (2006.01) Medicinal preparations characterised by special physical form - Particulate form, e.g. powders

A61K 9/28 (2006.01) Medicinal preparations characterised by special physical form - Dragees

C07D 307/88 (2006.01) Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

Event Publications

28 June 2007 Complete Application Filed

5 July 2007 Application Open to Public Inspection

  Published as AU-B-2007202693

10 December 2009 Application Accepted

  Published as AU-B-2007202693

8 April 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2007202694-Showcase

2007202692-Ultra-wide band differential input/output, high frequency amplifier in an integrated circuit